Pharmaceutical group GlaxoSmithKline said its majority-owned HIV business would buy drugs at different stages of development from U.S. rival Bristol-Myers Squibb for an initial $350 million.
GSK said the acquisitions would provide ViiV Healthcare, its HIV unit in which Pfizer and Shionogi are junior partners, with new opportunities for growth.
{iframe}http://www.reuters.com/article/us-bristol-myers-m-a-gsk-idUSKBN0U10LZ20151218{/iframe}